12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

X-82: Phase I/II start

Next month, Xcovery will begin the open-label, dose-escalation, U.S. Phase I/II X82-OPH-102 trial to evaluate oral X-82 in up to 20 patients with wet AMD. Lucentis ranibizumab rescue treatment...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >